SCHEMBL719582

SCHEMBL719582

CCC(C)OB(OC(C)CC)OC(C)CC

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27534354 0.97 TSHR (0.30) TSHR
SCHEMBL29008995 0.97 TSHR (0.30) TSHR
SCHEMBL26351459 0.91
SCHEMBL10972928 0.87 LMNA (0.30)
SCHEMBL9817385 0.85
SCHEMBL9817610 0.83
SCHEMBL10974235 0.79 FAAH (0.39)
SCHEMBL1502286 0.75
SCHEMBL10973345 0.75 TSHR (0.35) TSHR
SCHEMBL28128620 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119973099-A Magnetic powder modifier, preparation method and application thereof, and production method of neodymium-iron-boron magnet 包头稀土研究院 2025-05-13 CN claimed
WO-2024235068-A1 ADHESION ENHANCING COMPOSITION, ADHESIVE COMPOSITIONS COMPRISING THE SAME AND A PROCESS FOR PREPARING THE SAME MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2024-11-21 WO claimed
CN-118956291-A Adhesion enhancing composition, adhesive composition comprising the same, and method of preparing the adhesion enhancing composition 迈图高新材料公司 2024-11-15 CN claimed
US-20220275007-A1 FLOW REACTION PROCESS FOR MANUFACTURE OF BORON-CONTAINING AGROCHEMICALS 5METIS, INC. 2022-09-01 US claimed
WO-2021021932-A1 FLOW REACTION PROCESS FOR MANUFACTURE OF BORON-CONTAINING AGROCHEMICALS Boragen, Inc. (US) 2021-02-04 WO claimed
US-20090199992-A1 SULFUR DIOXIDE-CURED EPOXY ACRYLATE FOUNDRY BINDER SYSTEM HA-INTERNATIONAL, LLC (US) 2009-08-13 US claimed
US-20080306257-A1 Syntheses and Preparations of Narwedine and Related Novel Compounds MEDICHEM, S.A. (ES) 2008-12-11 US claimed
US-20080139830-A1 Preparation of substituted aminoanthraquinones LANXESS DEUTSCHLAND GMBH 2008-06-12 US claimed
EP-1066250-B1 A CONVERGENT SYNTHESIS OF ALPHA-ARYL-BETA KETONITRILES BRISTOL MYERS SQUIBB PHARMA CO (US) 2005-03-02 EP claimed
EP-1461497-A1 PROCESS FOR MANUFACTURING A CELLULOSIC PAPER PRODUCT EXHIBITING REDUCED MALODOR KIMBERLY-CLARK CORPORATION (US) 2004-09-29 EP claimed
WO-2003057985-A1 PROCESS FOR MANUFACTURING A CELLULOSIC PAPER PRODUCT EXHIBITING REDUCED MALODOR KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO claimed
US-20030131961-A1 Process for manufacturing a cellulosic paper product exhibiting reduced malodor KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-17 US claimed
EP-1066250-A2 A CONVERGENT SYNTHESIS OF ALPHA-ARYL-BETA KETONITRILES Du Pont Pharmaceuticals Company (US) 2001-01-10 EP claimed
US-6107508-A SYNTHETIC INTERMEDIATES IN THE PREPARATION OF A SERIES OF BIOLOGICALLY IMPORTANT MOLECULES SUCH AS CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS DUPONT PHARMACEUTICALS COMPANY (US) 2000-08-22 US claimed
WO-1999051568-A2 A CONVERGENT SYNTHESIS OF α-ARYL-β-KETONITRILES DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-14 WO claimed
US-4623360-A ANTICOKING, ORGANIC NITRATES AND BORATED PHENOLIC COMPOUND ETHYL CORPORATION (US) 1986-11-18 US claimed
US-20260085145-A1 CURABLE RESIN, CURABLE RESIN COMPOSITION, AND CURED ARTICLE DAINIPPON INK & CHEMICALS (JP) 2026-03-26 US disclosed
EP-4628517-A1 CURABLE RESIN, CURABLE RESIN COMPOSITION, AND CURED ARTICLE DIC Corporation (JP) 2025-10-08 EP disclosed
EP-0012198-A1 Allylic rearrangement process SCM CORPORATION (US) 1980-06-25 EP disclosed
US-3935248-A POLYAMIDES IMPERIAL CHEMICAL INDUSTRIES LIMITED (EN) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085145-A1 CURABLE RESIN, CURABLE RESIN COMPOSITION, AND CURED ARTICLE MAT1A, CAPZA1, CDH1 TSHR 3836/4885
US-20080306257-A1 Syntheses and Preparations of Narwedine and Related Novel Compounds GNE, GALE, GNMT TSHR 3614/4885
US-20220275007-A1 FLOW REACTION PROCESS FOR MANUFACTURE OF BORON-CONTAINING AGROCHEMICALS BROX, SQLE, BMX TSHR 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.